Acute Myeloid Leukemia With KMT2A Rearrangement
Oncology
Prevalence
6.0 / 100K
Incidence
4.3 / 100K/yr
4 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(2)
Phase 2(1)
| Drug | Company |
|---|---|
| daunorubicin | Merus N.V. (MRUS) |
Phase 1(1)
| Drug | Company |
|---|---|
| Revumenib | Merus N.V. (MRUS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Acute Myeloid Leukemia With KMT2A Rearrangement?
BioSniper tracks 4 drugs in development for Acute Myeloid Leukemia With KMT2A Rearrangement across 1 company.
How many clinical trials target Acute Myeloid Leukemia With KMT2A Rearrangement?
There are 1 clinical trial targeting Acute Myeloid Leukemia With KMT2A Rearrangement tracked by BioSniper.
What is the prevalence of Acute Myeloid Leukemia With KMT2A Rearrangement?
The estimated prevalence of Acute Myeloid Leukemia With KMT2A Rearrangement is approximately 6.0 per 100,000 population.
Deep-dive into Acute Myeloid Leukemia With KMT2A Rearrangement
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis